PPI preparations in the retail market sell 2.6 billion domestically produced Class 1 new drugs for production

On October 22, Sihuan Pharmaceutical issued an announcement stating that its subsidiary Xuanzhu Biologics’ application for the listing of a new class 1 drug, Anaprazole Sodium Enteric-coated Tablets, has been accepted by the CDE.
It is reported that the new drug is a new generation of PPI inhibitors for use in For the treatment of duodenal ulcer, the safety and symptom relief of this new drug are the best Best-in-class products of its kind
.
Figure 1: The completed clinical situation of Anaprazole sodium enteric-coated tabletsSource: China Drug Clinical Trial Publicity Library of MeinenetAt present, PPI inhibitors on the domestic market mainly involve omeprazole, rabeprazole, esomeprazole, pantoprazole, ilaprazole and lansoprazole.
In recent years, PPI preparations have remained in the retail market With rapid growth, the latest data from Meinnet.
com shows that the total sales of these six categories in physical pharmacies in Chinese cities in 2021 are expected to exceed 2.
6 billion yuan
.
Table 1: 2021E treatment peptic ulcer drugs TOP10 varieties (unit: 100 million yuan)Source: Mi Nei.
com, China's urban physical pharmacy terminal layoutIn 2021, among the TOP10 varieties of peptic ulcer drugs for the terminal treatment of peptic ulcer in physical pharmacies in Chinese cities, omeprazole, rabeprazole, esomeprazole, pantoprazole and ilaprazole have occupied the top five seats, of which Esomeprazole and ilaprazole are expected to achieve double-digit growth rates
.
Figure 2: Sales of ilaprazole in the retail market (unit: ten thousand yuan)　　Source: Mi Nei.
com, China's urban physical pharmacy terminal layout 　　Judging from the current situation, the competition among omeprazole, rabeprazole, esomeprazole, pantoprazole and lansoprazole is very fierce, and ilaprazole, as the exclusive variety of Livzon, is almost The annual growth rate is fierce.
In 2015, it ranked only TOP11 in the treatment of peptic ulcer drugs , and it is expected to rise to TOP5 in 2021
.
Although the price of this product has fallen sharply after entering the medical insurance, it has maintained rapid growth in the retail market
.
Anaprazole sodium enteric-coated tablets as a new PPI inhibitor, if successfully approved for marketing, it is expected to refer to the growth path of ilaprazole and achieve a breakthrough
.
 　　Source: CDE official website, Minet database 　　Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
　　On October 22, Sihuan Pharmaceutical issued an announcement stating that its subsidiary Xuanzhu Biologics’ application for the listing of a new class 1 drug, Anaprazole Sodium Enteric-coated Tablets, has been accepted by the CDE.
It is reported that the new drug is a new generation of PPI inhibitors for use in For the treatment of duodenal ulcer, the safety and symptom relief of this new drug are the best Best-in-class products of its kind
.
 　　Figure 1: The completed clinical situation of Anaprazole sodium enteric-coated tablets　　Source: China Drug Clinical Trial Publicity Library of Meinenet 　　At present, PPI inhibitors on the domestic market mainly involve omeprazole, rabeprazole, esomeprazole, pantoprazole, ilaprazole and lansoprazole.
In recent years, PPI preparations have remained in the retail market With rapid growth, the latest data from Meinnet.
com shows that the total sales of these six categories in physical pharmacies in Chinese cities in 2021 are expected to exceed 2.
6 billion yuan
.
 　　Table 1: 2021E treatment peptic ulcer drugs TOP10 varieties (unit: 100 million yuan)　　Source: Mi Nei.
com, China's urban physical pharmacy terminal layout 　　In 2021, among the TOP10 varieties of peptic ulcer drugs for the terminal treatment of peptic ulcer in physical pharmacies in Chinese cities, omeprazole, rabeprazole, esomeprazole, pantoprazole and ilaprazole have occupied the top five seats, of which Esomeprazole and ilaprazole are expected to achieve double-digit growth rates
.
 　　Figure 2: Sales of ilaprazole in the retail market (unit: ten thousand yuan)　　Source: Mi Nei.
com, China's urban physical pharmacy terminal layout 　　Judging from the current situation, the competition among omeprazole, rabeprazole, esomeprazole, pantoprazole and lansoprazole is very fierce, and ilaprazole, as the exclusive variety of Livzon, is almost The annual growth rate is fierce.
In 2015, it ranked only TOP11 in the treatment of peptic ulcer drugs , and it is expected to rise to TOP5 in 2021
.
Although the price of this product has fallen sharply after entering the medical insurance, it has maintained rapid growth in the retail market
.
Anaprazole sodium enteric-coated tablets as a new PPI inhibitor, if successfully approved for marketing, it is expected to refer to the growth path of ilaprazole and achieve a breakthrough
.
 　　Source: CDE official website, Minet database 　　Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
　　On October 22, Sihuan Pharmaceutical issued an announcement stating that its subsidiary Xuanzhu Biologics’ application for the listing of a new class 1 drug, Anaprazole Sodium Enteric-coated Tablets, has been accepted by the CDE.
It is reported that the new drug is a new generation of PPI inhibitors for use in For the treatment of duodenal ulcer, the safety and symptom relief of this new drug are the best Best-in-class products of its kind
.
 　　Figure 1: The completed clinical situation of Anaprazole sodium enteric-coated tablets　　　Source: China Drug Clinical Trial Publicity Library of Meinenet 　　At present, PPI inhibitors on the domestic market mainly involve omeprazole, rabeprazole, esomeprazole, pantoprazole, ilaprazole and lansoprazole.
In recent years, PPI preparations have remained in the retail market With rapid growth, the latest data from Meinnet.
com shows that the total sales of these six categories in physical pharmacies in Chinese cities in 2021 are expected to exceed 2.
6 billion yuan
.
 　　Table 1: 2021E treatment peptic ulcer drugs TOP10 varieties (unit: 100 million yuan)　　Source: Mi Nei.
com, China's urban physical pharmacy terminal layout 　　In 2021, among the TOP10 varieties of peptic ulcer drugs for the terminal treatment of peptic ulcer in physical pharmacies in Chinese cities, omeprazole, rabeprazole, esomeprazole, pantoprazole and ilaprazole have occupied the top five seats, of which Esomeprazole and ilaprazole are expected to achieve double-digit growth rates
.
 　　Figure 2: Sales of ilaprazole in the retail market (unit: ten thousand yuan)　　　　Source: Mi Nei.
com, China's urban physical pharmacy terminal layout 　　Judging from the current situation, the competition among omeprazole, rabeprazole, esomeprazole, pantoprazole and lansoprazole is very fierce, and ilaprazole, as the exclusive variety of Livzon, is almost The annual growth rate is fierce.
In 2015, it ranked only TOP11 in the treatment of peptic ulcer drugs , and it is expected to rise to TOP5 in 2021
.
Although the price of this product has fallen sharply after entering the medical insurance, it has maintained rapid growth in the retail market
.
Anaprazole sodium enteric-coated tablets as a new PPI inhibitor, if successfully approved for marketing, it is expected to refer to the growth path of ilaprazole and achieve a breakthrough
.
Medicine medicine 　　Source: CDE official website, Minet database　　 　　Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
pharmacy